UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/579,587	07/14/2008	Hans-Georg Capraro	33512-US-PCT	4765
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 220 MASSACHUSETTS AVENUE			EXAMINER	
			REESE, HEIDI L	
CAMBRIDGE, MA 02139		ART UNIT	PAPER NUMBER	
			1625	
			NOTIFICATION DATE	DELIVERY MODE
			10/14/2011	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

NIBR.MAILDATA@NOVARTIS.COM PATRICIA.HOFSTETTER@NOVARTIS.COM

	Application No.	Applicant(s)		
Nation of Abandonmont	10/579,587	CAPRARO ET AL.		
Notice of Abandonment	Examiner	Art Unit		
	Heidi Reese	1625		
The MAILING DATE of this communication app	ears on the cover sheet with the c	orrespondence address		
This application is abandoned in view of:				
 Applicant's failure to timely file a proper reply to the Office letter mailed on 14 March 2011. (a) A reply was received on (with a Certificate of Mailing or Transmission dated), which is after the expiration of the period for reply (including a total extension of time of month(s)) which expired on (b) A proposed reply was received on, but it does not constitute a proper reply under 37 CFR 1.113 (a) to the final rejection. (A proper reply under 37 CFR 1.113 to a final rejection consists only of: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114). (c) A reply was received on but it does not constitute a proper reply, or a bona fide attempt at a proper reply, to the non-final rejection. See 37 CFR 1.85(a) and 1.111. (See explanation in box 7 below). (d) No reply has been received. 				
 2. Applicant's failure to timely pay the required issue fee and publication fee, if applicable, within the statutory period of three months from the mailing date of the Notice of Allowance (PTOL-85). (a) The issue fee and publication fee, if applicable, was received on (with a Certificate of Mailing or Transmission dated), which is after the expiration of the statutory period for payment of the issue fee (and publication fee) set in the Notice of Allowance (PTOL-85). (b) The submitted fee of \$ is insufficient. A balance of \$ is due. The issue fee required by 37 CFR 1.18 is \$ The publication fee, if required by 37 CFR 1.18(d), is \$ (c) The issue fee and publication fee, if applicable, has not been received. 				
 3. Applicant's failure to timely file corrected drawings as required by, and within the three-month period set in, the Notice of Allowability (PTO-37). (a) Proposed corrected drawings were received on (with a Certificate of Mailing or Transmission dated), which is after the expiration of the period for reply. (b) No corrected drawings have been received. 				
4. The letter of express abandonment which is signed by the attorney or agent of record, the assignee of the entire interest, or all of the applicants.				
5. The letter of express abandonment which is signed by an attorney or agent (acting in a representative capacity under 37 CFR 1.34(a)) upon the filing of a continuing application.				
6. The decision by the Board of Patent Appeals and Interference rendered on and because the period for seeking court review of the decision has expired and there are no allowed claims.				
7. The reason(s) below:				
/Janet L. Andres/	/Heidi Reese/			
Supervisory Patent Examiner, Art Unit 1625 Petitions to revive under 37 CFR 1.137(a) or (b), or requests to withdra	Examiner, Art Unit 1625	CER 1 181 should be promptly filed to		
remions to revive under 37 OFR 1.13/(a) or (b), or requests to withdra	w the holding of abalidofilletit under 3/	OF TELLOT, SHOULD be promptly med to		